CLARENCE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that scientists with The Centers for Disease Control and Prevention (CDC) published a detailed characterization of the Company’s SPECTRUM® Variable Nicotine Research Cigarettes, calling 22nd Century’s proprietary cigarettes an “important tool in clinical studies for investigating… the impact of reduced nicotine cigarettes on nicotine addiction…” Published in Tobacco Regulatory Science, the independent study was conducted by a prestigious team of 18 senior CDC scientists. Click here for a link to the complete article.
Based in Oak Ridge, Tennessee and Atlanta, Georgia, the independent scientific researchers critically showed that there is a remarkable overall similarity in the chemistry and physical properties of SPECTRUM® cigarettes as compared to commercial cigarettes – with the noted exception of nicotine content which “range[s] from very low to within the range reported for commercial products (0.28 – 25.0 mg/g).”
22nd Century’s Vice President for Plant Biotechnology, Dr. Paul Rushton, reported: “The CDC researchers also showed that 22nd Century’s Very Low Nicotine SPECTRUM® cigarettes have reduced levels of the cancer causing compounds NNN and NNK. The NNN levels of SPECTRUM® cigarettes are within the lower one-third of the concentration range reported for commercial cigarette products. The NNK levels in SPECTRUM® cigarettes were lower than the lowest published levels of NNK for commercial cigarette products.” (emphasis added)
22nd Century is the only company in the world capable of producing combustible cigarettes containing naturally grown tobacco with non-addictive levels of nicotine. The independent researchers indicated that SPECTRUM® variable nicotine cigarettes will help regulatory agencies make vital decisions on the impact of reduced nicotine levels for product addictiveness and smoking cessation success. The study scientists also pointed out that more research using the Company’s proprietary SPECTRUM® cigarettes is expected due to multiple funding opportunities by the National Institutes of Health (https://prevention.nih.gov/tobacco-regulatory-science-program) and the FDA (http://www.fda.gov/TobaccoProducts/PublicHealthScienceResearch/default.htm). Furthermore, as announced in May 2016, 22nd Century has launched a new initiative to make the Company’s proprietary variable nicotine research cigarettes available to accredited scientists and governments around the globe. These new research cigarettes will be available in any configuration and in any style requested by researchers.
“The CDC researchers’ independent analysis of our SPECTRUM® research cigarettes – and the multiple funding opportunities stemming from the NIH and the FDA for further studies – confirms that 22nd Century’s proprietary Very Low Nicotine cigarettes are poised to make a major difference in the smoking cessation and tobacco harm reduction arenas,” explained Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group. “The rapidly growing body of research surrounding our SPECTRUM® research cigarettes is prompting public health officials around the world to consider policies that allow consumers a choice between 22nd Century’s Very Low Nicotine cigarettes and conventional brands. Our product represents an important and fundamental change in the industry.”
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company’s primary mission is to reduce the harm caused by smoking. 22nd Century currently owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications around the world. Visit www.xxiicentury.com for more information.
Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2015, filed on February 18, 2016, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.
